title: New Translational Research in the Medical Management of Orbital Melanoma.
abstract: New translational research has paved the way for more optimistic management of melanoma. Medications targeting oncogenic signaling cascades and immune regulatory molecules have significantly improved overall survival for patients with metastatic melanoma. While isolated, operable orbital melanoma may still benefit from surgery, there potentially is an opportunity to provide patients with neoadjuvant systemic therapy with sustainable long-term effects. Additionally, patients with non-resectable orbital melanoma can benefit from systemic treatment.
authors.affiliation: a Ophthalmic Plastic Surgery Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School , Boston , Massachusetts , USA and.
authors.forename: Lora
authors.initials: L
authors.lastname: Dagi Glass
authors.affiliation: b Massachusetts General Hospital Cancer Center, Harvard Medical School , Boston , Massachusetts , USA.
authors.forename: Ryan
authors.initials: R
authors.lastname: Sullivan
authors.affiliation: a Ophthalmic Plastic Surgery Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School , Boston , Massachusetts , USA and.
authors.forename: Suzanne K
authors.initials: SK
authors.lastname: Freitag
mesh_terms: D019138:Antibodies, Blocking / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D058990:Molecular Targeted Therapy; D009918:Orbital Neoplasms / Q000188:drug therapy*; D057170:Translational Research, Biomedical
chemical_list: D019138:Antibodies, Blocking; D000970:Antineoplastic Agents
keywords: Dabrafenib; ipilimumab; nivolumab; pembrolizumab; trametinib; vemurafinib